UbiVac

UbiVac Announces Clinical Trial Collaboration with Bristol Myers Squibb on Combination Immunotherapy for Advanced Triple Negative Breast Cancer

Retrieved on: 
Tuesday, June 9, 2020
Pharmaceutical, Health, Oncology, Clinical trials, Medicine, Vaccination, Clinical medicine, Health, Breast cancer, RTT, Triple-negative breast cancer, Cancer vaccine, HER2/neu, Vaccine, Tumor antigen vaccine, Neuvenge, UbiVac’s Innovative Cancer Vaccine Technology, UbiVac

The Phase 1b multicenter trial will test the hypothesis that combination immunotherapy with the DPV-001 cancer vaccine and anti-OX40 will augment anticancer immunity in patients with advanced triple negative breast cancer.

Key Points: 
  • The Phase 1b multicenter trial will test the hypothesis that combination immunotherapy with the DPV-001 cancer vaccine and anti-OX40 will augment anticancer immunity in patients with advanced triple negative breast cancer.
  • Triple Negative Breast Cancer is negative for estrogen receptors, progesterone receptors and HER2 receptors, and therefore treatment options are limited.
  • We believe that cutting-edge immunotherapy combinations have the potential to induce long-lasting anticancer immunity and translate into clinical responses in patients with triple negative breast cancer.
  • UbiVac is a privately held, clinical stage immunotherapy company engaged in the research and development of therapeutic vaccines to combat cancer.